Literature DB >> 8543829

Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.

V D Miletic1, C G Hester, M M Frank.   

Abstract

Intravenous Ig, composed principally of IgG, prevents complement attack by inhibiting C3 and C4 uptake onto target cells and tissues. Using two different models, Ab-sensitized SRBC and BSA-anti BSA solid phase immune complexes, we have examined the complement inhibitory capacity of three Ig classes (IgG, IgM, IgA) focussing on inhibition of C4 uptake. It was found that on both a weight and molar basis, monomeric serum IgA and IgM were far more active than IgG (weight efficiency ratios were 1.0, 20.8, and 236.3, and molar efficiency ratios 1.0, 24.0, and 1382.9 for polyclonal IgG, IgA1, and IgM, respectively). Monoclonal IgM were less active than polyclonal IgM (50% inhibition was achieved in SRBC model by 0.022, 0.30, 1.6, and 1.6 mg/ml of polyclonal IgM and monoclonal IgM from patients Lew, Will, and Pri). Secretory IgA was less active than serum IgA1 and similar in inhibitory activity to IgG (weight and molar efficiency ratios 1.5 and 0.6 compared with IgG). All tested preparations were less active in the solid phase immune complex model than in the sensitized cell model. A mixture of Igs of different isotypes was somewhat more active than any isotype alone. These results suggest that polyclonal serum IgA and IgM can also be considered for active therapy in diseases accompanied by the activation of classical complement pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543829

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

2.  Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.

Authors:  H Shoham-Kessary; Y Naot; H Gershon
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 3.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 4.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

5.  7th International Immunoglobulin Conference: Mechanisms of action.

Authors:  M Basta; D R Branch
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

6.  Serum cortisol, immunoglobulins and some complements among depressed patients.

Authors:  Hussein Kadhem Al-Hakeim
Journal:  Indian J Clin Biochem       Date:  2008-03-06

Review 7.  Immunoglobulin in the control of complement action.

Authors:  M M Frank; V D Miletic; H Jiang
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

8.  BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer.

Authors:  Laëtitia Le Pottier; Boutahar Bendaoud; Maryvonne Dueymes; Capucine Daridon; Pierre Youinou; Yehuda Shoenfeld; Jacques-Olivier Pers
Journal:  J Clin Immunol       Date:  2007-03-29       Impact factor: 8.542

9.  TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells.

Authors:  Mayara Garcia de Mattos Barbosa; Adam R Lefferts; Daniel Huynh; Hui Liu; Yu Zhang; Beverly Fu; Jenna Barnes; Milagros Samaniego; Richard J Bram; Raif S Geha; Ariella Shikanov; Eline T Luning Prak; Evan A Farkash; Jeffrey L Platt; Marilia Cascalho
Journal:  JCI Insight       Date:  2021-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.